Abstract
Abstract Tuberculosis remains a serious global epidemic and with the rise of multi-drug resistant strains, an efficacious vaccine solution is imperative. Vaccines currently being developed for Mtb utilize protein antigens, which target MHC-restricted conventional T cells, overlooking the potential of Mycobacterium tuberculosis (Mtb) lipid antigens such as mycolic acid (MA), a key lipid found in Mtb cell wall. Mycobacterial lipids are presented by group 1 CD1 molecules (CD1a, b, c) to cognate T cells. Group 1 CD1-restricted T cells can be identified in patients with TB and have been shown to provide protection in Mtb infection. Using biocontinuous nanospheres (BCNs), a type of self-assembled nanostructure able to load both hydrophobic and hydrophilic molecules, we have created a vaccine containing MA. We found that MA BCN is able to effectively activate CD1b-restricted MA-specific T cells in vitro and in vivo. Interestingly, we discovered that MA persists within lung alveolar macrophages for at least 6 weeks after intratracheal vaccination with MA BCN. Antigen archiving was in part due to the encapsulation of MA within BCN. Nanoparticle vaccinations carrying lipid antigens may thus lead to persistent depots of antigen that could offer long-lasting immune response and protection. Supported by grants from NIH (5R01AI145345-03, 1F30AI157314-01, 5T32GM008152-35)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
